Citation Impact
Citing Papers
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
2019 StandoutScienceNobel
Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy
2008
Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders
2009
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro
2010 StandoutScienceNobel
G Protein-coupled Receptor Kinases Phosphorylate LRP6 in the Wnt Pathway
2009 StandoutNobel
Dasatinib
2009
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
The FGF family: biology, pathophysiology and therapy
2009 Standout
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
2007
Influence of Metabolism on Epigenetics and Disease
2013 StandoutNobel
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
2005 StandoutNature
Chronic myelogenous leukemia
2001
Oncogenic kinase signalling
2001 StandoutNature
Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL
1997
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
Evolution of the cancer genome
2012
Chromatin structural elements and chromosomal translocations in leukemia
2006
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Anaplastic lymphoma kinase proteins in growth control and cancer
2004
Regulation of chromatin by histone modifications
2011 Standout
Building the Connectivity Map of epigenetics: Chromatin profiling by quantitative targeted mass spectrometry
2014
Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations
2004
Histone methylation: a dynamic mark in health, disease and inheritance
2012 Standout
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
2005 StandoutNature
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Genome-wide Detection of Allelic Imbalance Using Human SNPs and High-density DNA Arrays
2000
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
2001 Standout
High-Resolution Profiling of Histone Methylations in the Human Genome
2007 Standout
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of <i>FGFR1</i>
2002
Cellular signaling by fibroblast growth factor receptors
2005 Standout
Mechanisms of therapy-related carcinogenesis
2005
DNA topoisomerase II, genotoxicity, and cancer
2007
PRC2 mediated H3K27 methylations in cellular identity and cancer
2015
What causes cell death in Parkinson's disease?
2009
The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)
2011
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
2002
Angiogenesis in life, disease and medicine
2005 StandoutNature
Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses
2008
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing
2008
Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074
2004
The Biology of Chronic Myeloid Leukemia
1999
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
TET enzymes, TDG and the dynamics of DNA demethylation
2013 StandoutNature
Transplants across human leukocyte antigen barriers
2002
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
2004
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
2000
Chronic Eosinophilic Leukemias and the Myeloproliferative Variant of the Hypereosinophilic Syndrome
2007
Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
2018 StandoutNobel
Role of KIT and platelet-derived growth factor receptors as oncoproteins
2004
cdx4 mutants fail to specify blood progenitors and can be rescued by multiple hox genes
2003 Nature
Molecular genetics, natural history and the demise of childhood leukaemia
1999
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
The role of senescent cells in ageing
2014 StandoutNature
Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α
1998 StandoutNobel
Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients
2003
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation
2000 StandoutNatureNobel
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
An Overview of Real-Time Quantitative PCR: Applications to Quantify Cytokine Gene Expression
2001
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Chronic Myeloid Leukemia
1999
The role of fibroblast growth factors and their receptors in prostate cancer
2004
The Polycomb complex PRC2 and its mark in life
2011 StandoutNature
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
2009
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
2005
Fibroblast growth factor signaling in tumorigenesis
2005
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
2001 Standout
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
1999 StandoutScience
A Novel Fusion Between MOZ and the Nuclear Receptor Coactivator TIF2 in Acute Myeloid Leukemia
1998
Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice
2011
Nonimmunoglobulin target loci of activation-induced cytidine deaminase (AID) share unique features with immunoglobulin genes
2012 StandoutNobel
Imatinib (STI571)-Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells
2004
Gender Differences in UVB-Induced Skin Carcinogenesis, Inflammation, and DNA Damage
2007
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
The Prognostic Significance of Altered Cyclin-Dependent Kinase Inhibitors in Human Cancer
1999
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML
2004
Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC).
2000
Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation.
1999
Roles of nonhomologous end-joining pathways in surviving topoisomerase II–mediated DNA damage
2006
Illegitimate Cre-dependent chromosome rearrangements in transgenic mouse spermatids
2000 StandoutNobel
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
2004 StandoutScience
Control of skin cancer by the circadian rhythm
2011 StandoutNobel
Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia
2001
Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells
2012 StandoutNobel
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
1999
TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia
1996
The molecular biology of chronic myeloid leukemia
2000
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
2011 StandoutScience
Cancer Genome Landscapes
2013 StandoutScience
Molecular Genetics of Acute Lymphoblastic Leukemia
2005
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
2003
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
2000 StandoutScience
Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
2002 StandoutScience
Detection of nucleon correlations via pion double-charge-exchange reactions
1988 StandoutNobel
The Myeloproliferative Disorders
2006
Large-scale analysis of the human and mouse transcriptomes
2002 StandoutNobel
The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
2002 StandoutNobel
Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.
2001
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
2011 StandoutScience
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
2009
Energy levels of A = 21–44 nuclei (VI)
1978 Standout
Extending Healthy Life Span—From Yeast to Humans
2010 StandoutScience
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Acute Mixed Lineage Leukemia With an inv(8)(p11q13) Resulting in Fusion of the Genes for MOZ and TIF2
1998
A Novel Fusion Between MOZ and the Nuclear Receptor Coactivator TIF2 in Acute Myeloid Leukemia
1998
Works of Andreas Reiter being referenced
BCR‐ABL‐positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon‐α
1998
Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia
2002
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
2010
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies
2005
The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1
2005
Detection and quantification of residual disease in chronic myelogenous leukemia
2000
Variable numbers of BCR‐ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon‐α
1995
Transplantation of Megadoses of Purified Haploidentical Stem Cells
1999
Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score
1997
Should a platelet limit of 600 × 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages
1998
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2‐PDGFRA fusion gene
2006
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
2009
Fibroblast Growth Factor Receptor and Platelet-Derived Growth Factor Receptor Abnormalities in Eosinophilic Myeloproliferative Disorders
2008
Current trends in the management of chronic myelogenous leukemia
2000
Molecular Monitoring of Residual Disease in Chronic Myelogenous Leukemia Patients After Therapy
1998
DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia
2005
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR
1999
Tyrosine kinase fusion genes in chronic myeloproliferative diseases
2002
Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
2007
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor gene
2007
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins
2001
Fusion of ETV6 to the Caudal-Related Homeobox Gene CDX2 in Acute Myeloid Leukemia With the t(12;13)(p13;q12)
1999
Study of (3He,n) reactions on nuclei in the 2s-1d shell
1972
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
2005
Acute lymphoblastic leukemia of childhood: identification of two distinct regions of deletion on the short arm of chromosome 12 in the region of TEL and KIP1
1996
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction
1996
Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood
1995
Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission
2000
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
2009
Abnormalities of Chromosome Band 8p11 in Leukemia: Two Clinical Syndromes Can Be Distinguished on the Basis of MOZ Involvement
1997
Die 8p11-myeloproliferative Erkrankung
1999
Allelotype analysis of childhood acute lymphoblastic leukemia.
1995
Consistent Fusion of ZNF198 to the Fibroblast Growth Factor Receptor-1 in the t(8;13)(p11;q12) Myeloproliferative Syndrome
1998